Výsledky vyhledávání

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Mechanistic investigation of liver injury induced by BMS-932481, an experimental ɣ-secretase modulator.

Autor: Zhuo X; Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Wallingford, Connecticut, USA., Howell BA; Simulations Plus, Inc., Research Triangle Park, North Carolina, USA., Shen H; Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Lawrenceville, New Jersey, USA., Woodhead JL; Simulations Plus, Inc., Research Triangle Park, North Carolina, USA., Mosure K; Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Wallingford, Connecticut, USA., Zhang Y; Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Lawrenceville, New Jersey, USA., Scialis RJ; Nonclinical Disposition and Pharmacokinetics, Bristol Myers Squibb, Lawrenceville, New Jersey, USA., Iyer R; Nonclinical Disposition and Pharmacokinetics, Bristol Myers Squibb, Lawrenceville, New Jersey, USA., Sun Y; Automation and Assay Technologies, Bristol Myers Squibb, Lawrenceville, New Jersey, USA., Boy KM; Small Molecule Drug Discovery, Bristol Myers Squibb, Wallingford, Connecticut, USA., Lentz KA; Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Wallingford, Connecticut, USA., Denton RR; Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Wallingford, Connecticut, USA., Soars MG; Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Wallingford, Connecticut, USA., Johnson BM; Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Wallingford, Connecticut, USA., Humphreys WG; Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Lawrenceville, New Jersey, USA.

Publikováno v: Toxicological sciences : an official journal of the Society of Toxicology [Toxicol Sci] 2023 Jul 28; Vol. 194 (2), pp. 235-245.

Zobrazit plný text záznamu

Report

Discovery of pyrrolo[2,1- f ][1,2,4]triazine-based inhibitors of adaptor protein 2-associated kinase 1 for the treatment of pain.

Autor: Dzierba CD; Small Molecule Drug Discovery, Bristol Myers Squibb, Research and Development, 250 Water St, Cambridge, MA 02141 USA., Dasgupta B; Department of Neuroscience Chemistry, Bristol Myers Squibb, Bristol Myers Squibb Company, Research and Development, 5 Research Parkway, Wallingford, CT 06492 USA., Karageorge G; Department of Neuroscience Chemistry, Bristol Myers Squibb, Bristol Myers Squibb Company, Research and Development, 5 Research Parkway, Wallingford, CT 06492 USA., Kostich W; Department of Neuroscience Biology, Bristol Myers Squibb, Bristol Myers Squibb Company, Research and Development, 5 Research Parkway, Wallingford, CT 06492 USA., Hamman B; Lexicon Pharmaceuticals 8800 Technology Forest Place, The Woodlands, TX 77381 USA., Allen J; Lexicon Pharmaceuticals 8800 Technology Forest Place, The Woodlands, TX 77381 USA., Esposito KM; Department of Leads Discovery and Optimization, Bristol Myers Squibb, Bristol Myers Squibb Company, Research and Development, 5 Research Parkway, Wallingford, CT 06492 USA., Padmanabha R; Department of Leads Discovery and Optimization, Bristol Myers Squibb, Research and Development, P.O. Box 5400, Princeton, NJ 08543 USA., Grace J; Department of Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Bristol Myers Squibb Company, Research and Development, 5 Research Parkway, Wallingford, CT 06492 USA., Lentz K; Department of Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Bristol Myers Squibb Company, Research and Development, 5 Research Parkway, Wallingford, CT 06492 USA., Morrison J; Department of Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Bristol Myers Squibb Company, Research and Development, 5 Research Parkway, Wallingford, CT 06492 USA., Morgan D; Department of Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Bristol Myers Squibb Company, Research and Development, 5 Research Parkway, Wallingford, CT 06492 USA., Easton A; Department of Neuroscience Biology, Bristol Myers Squibb, Bristol Myers Squibb Company, Research and Development, 5 Research Parkway, Wallingford, CT 06492 USA., Bourin C; Department of Neuroscience Biology, Bristol Myers Squibb, Bristol Myers Squibb Company, Research and Development, 5 Research Parkway, Wallingford, CT 06492 USA., Browning MR; Department of Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Bristol Myers Squibb Company, Research and Development, 5 Research Parkway, Wallingford, CT 06492 USA., Rajamani R; Department of Molecular Structure and Design, Bristol Myers Squibb, Bristol Myers Squibb Company, Research and Development, 5 Research Parkway, Wallingford, CT 06492 USA., Good A; Department of Molecular Structure and Design, Bristol Myers Squibb, Bristol Myers Squibb Company, Research and Development, 5 Research Parkway, Wallingford, CT 06492 USA., Parker DD; Department of Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Bristol Myers Squibb Company, Research and Development, 5 Research Parkway, Wallingford, CT 06492 USA., Muckelbauer JK; Department of Molecular Structure and Design, Bristol Myers Squibb, Research and Development, P.O. Box 5400, Princeton, NJ 08543 USA., Khan J; Department of Molecular Structure and Design, Bristol Myers Squibb, Research and Development, P.O. Box 5400, Princeton, NJ 08543 USA., Camac D; Department of Molecular Structure and Design, Bristol Myers Squibb, Research and Development, P.O. Box 5400, Princeton, NJ 08543 USA., Ghosh K; Biocon-Bristol Myers Squibb Research and Development Center, Biocon Park, Plot No. 2 & 3, Bommasandra Phase IV, Jigani Link Road, Bangalore, 560099 India., Halan V; Biocon-Bristol Myers Squibb Research and Development Center, Biocon Park, Plot No. 2 & 3, Bommasandra Phase IV, Jigani Link Road, Bangalore, 560099 India., Lippy JS; Department of Leads Discovery and Optimization, Bristol Myers Squibb, Research and Development, P.O. Box 5400, Princeton, NJ 08543 USA., Santone KS; Department of Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Bristol Myers Squibb Company, Research and Development, 5 Research Parkway, Wallingford, CT 06492 USA., Denton RR; Department of Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Research and Development, 250 Water St, Cambridge, MA 02141 USA., Westphal R; Department of Neuroscience Biology, Bristol Myers Squibb, Bristol Myers Squibb Company, Research and Development, 5 Research Parkway, Wallingford, CT 06492 USA., Bristow LJ; Department of Neuroscience Biology, Bristol Myers Squibb, Bristol Myers Squibb Company, Research and Development, 5 Research Parkway, Wallingford, CT 06492 USA., Conway CM; Department of Neuroscience Biology, Bristol Myers Squibb, Bristol Myers Squibb Company, Research and Development, 5 Research Parkway, Wallingford, CT 06492 USA., Bronson JJ; Small Molecule Drug Discovery, Bristol Myers Squibb, Research and Development, 250 Water St, Cambridge, MA 02141 USA., Macor JE; Department of Neuroscience Chemistry, Bristol Myers Squibb, Bristol Myers Squibb Company, Research and Development, 5 Research Parkway, Wallingford, CT 06492 USA.

Publikováno v: Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents [Med Chem Res] 2023 Jun 03, pp. 1-7. Date of Electronic Publication: 2023 Jun 03.

Zobrazit plný text záznamu

Akademický článek

Synthesis of functionalized derivatives of the gamma-secretase modulator BMS-932481 and identification of its major metabolite.

Autor: Zhang Y; Neuroscience Discovery Chemistry, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, CT 06492, United States. Electronic address: yunhui.zhang@bms.com., Boy KM; Neuroscience Discovery Chemistry, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, CT 06492, United States., Wu YJ; Neuroscience Discovery Chemistry, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, CT 06492, United States., Ramirez A; Process Research and Development, Bristol-Myers Squibb, 1 Squibb Drive, New Brunswick, NJ 08903, United States., Toyn JH; Neuroscience Discovery Biology, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, CT 06492, United States., Ahlijanian MK; Neuroscience Discovery Biology, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, CT 06492, United States., Albright CF; Neuroscience Discovery Biology, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, CT 06492, United States., Zhuo X; Department of Metabolism and Pharmcokinetics, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, CT 06492, United States., Johnson BM; Department of Metabolism and Pharmcokinetics, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, CT 06492, United States., Denton RR; Department of Toxicology, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, CT 06492, United States., Olson RE; Neuroscience Discovery Chemistry, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, CT 06492, United States., Thompson LA 3rd; Neuroscience Discovery Chemistry, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, CT 06492, United States., Macor JE; Neuroscience Discovery Chemistry, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, CT 06492, United States.

Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2020 Nov 15; Vol. 30 (22), pp. 127530. Date of Electronic Publication: 2020 Sep 02.

Zobrazit plný text záznamu

Akademický článek

Robust Translation of γ-Secretase Modulator Pharmacology across Preclinical Species and Human Subjects.

Autor: Toyn JH; Yale University, New Haven, Connecticut (J.H.T.); Bristol-Myers Squibb, Wallingford, Connecticut (K.M.B, J.R., Je.E.M., A.S.R., V.G., N.H., F.S., X.Z., W.C., K.S., R.R.D., L.A.T., J.M., J.G., K.A.L., R.P., L.C., D.M.D., C.F.A., R.E.O., M.K.A.); Pfizer Worldwide Research and Development, Groton, Connecticut (F.S., C.W.); Cantor Colburn LLP, Hartford, Connecticut (D.Z.); Kyowa Hakko Kirin Pharma, Princeton, New Jersey (F.B.); FORUM Pharmaceuticals, Waltham, Massachusetts (M.F.); GSK Consumer Healthcare, Parsippany, New Jersey (J.-S.W.); Bristol-Myers Squibb, Pennington, New Jersey (Jo.E.M., H.D.S., M.A.); Teva Pharmaceuticals, Frazer, Pennsylvania (M.G.); and Eisai, Woodcliff Lake, New Jersey (Q.H.)., Boy KM; Yale University, New Haven, Connecticut (J.H.T.); Bristol-Myers Squibb, Wallingford, Connecticut (K.M.B, J.R., Je.E.M., A.S.R., V.G., N.H., F.S., X.Z., W.C., K.S., R.R.D., L.A.T., J.M., J.G., K.A.L., R.P., L.C., D.M.D., C.F.A., R.E.O., M.K.A.); Pfizer Worldwide Research and Development, Groton, Connecticut (F.S., C.W.); Cantor Colburn LLP, Hartford, Connecticut (D.Z.); Kyowa Hakko Kirin Pharma, Princeton, New Jersey (F.B.); FORUM Pharmaceuticals, Waltham, Massachusetts (M.F.); GSK Consumer Healthcare, Parsippany, New Jersey (J.-S.W.); Bristol-Myers Squibb, Pennington, New Jersey (Jo.E.M., H.D.S., M.A.); Teva Pharmaceuticals, Frazer, Pennsylvania (M.G.); and Eisai, Woodcliff Lake, New Jersey (Q.H.)., Raybon J; Yale University, New Haven, Connecticut (J.H.T.); Bristol-Myers Squibb, Wallingford, Connecticut (K.M.B, J.R., Je.E.M., A.S.R., V.G., N.H., F.S., X.Z., W.C., K.S., R.R.D., L.A.T., J.M., J.G., K.A.L., R.P., L.C., D.M.D., C.F.A., R.E.O., M.K.A.); Pfizer Worldwide Research and Development, Groton, Connecticut (F.S., C.W.); Cantor Colburn LLP, Hartford, Connecticut (D.Z.); Kyowa Hakko Kirin Pharma, Princeton, New Jersey (F.B.); FORUM Pharmaceuticals, Waltham, Massachusetts (M.F.); GSK Consumer Healthcare, Parsippany, New Jersey (J.-S.W.); Bristol-Myers Squibb, Pennington, New Jersey (Jo.E.M., H.D.S., M.A.); Teva Pharmaceuticals, Frazer, Pennsylvania (M.G.); and Eisai, Woodcliff Lake, New Jersey (Q.H.)., Meredith JE Jr; Yale University, New Haven, Connecticut (J.H.T.); Bristol-Myers Squibb, Wallingford, Connecticut (K.M.B, J.R., Je.E.M., A.S.R., V.G., N.H., F.S., X.Z., W.C., K.S., R.R.D., L.A.T., J.M., J.G., K.A.L., R.P., L.C., D.M.D., C.F.A., R.E.O., M.K.A.); Pfizer Worldwide Research and Development, Groton, Connecticut (F.S., C.W.); Cantor Colburn LLP, Hartford, Connecticut (D.Z.); Kyowa Hakko Kirin Pharma, Princeton, New Jersey (F.B.); FORUM Pharmaceuticals, Waltham, Massachusetts (M.F.); GSK Consumer Healthcare, Parsippany, New Jersey (J.-S.W.); Bristol-Myers Squibb, Pennington, New Jersey (Jo.E.M., H.D.S., M.A.); Teva Pharmaceuticals, Frazer, Pennsylvania (M.G.); and Eisai, Woodcliff Lake, New Jersey (Q.H.)., Robertson AS; Yale University, New Haven, Connecticut (J.H.T.); Bristol-Myers Squibb, Wallingford, Connecticut (K.M.B, J.R., Je.E.M., A.S.R., V.G., N.H., F.S., X.Z., W.C., K.S., R.R.D., L.A.T., J.M., J.G., K.A.L., R.P., L.C., D.M.D., C.F.A., R.E.O., M.K.A.); Pfizer Worldwide Research and Development, Groton, Connecticut (F.S., C.W.); Cantor Colburn LLP, Hartford, Connecticut (D.Z.); Kyowa Hakko Kirin Pharma, Princeton, New Jersey (F.B.); FORUM Pharmaceuticals, Waltham, Massachusetts (M.F.); GSK Consumer Healthcare, Parsippany, New Jersey (J.-S.W.); Bristol-Myers Squibb, Pennington, New Jersey (Jo.E.M., H.D.S., M.A.); Teva Pharmaceuticals, Frazer, Pennsylvania (M.G.); and Eisai, Woodcliff Lake, New Jersey (Q.H.)., Guss V; Yale University, New Haven, Connecticut (J.H.T.); Bristol-Myers Squibb, Wallingford, Connecticut (K.M.B, J.R., Je.E.M., A.S.R., V.G., N.H., F.S., X.Z., W.C., K.S., R.R.D., L.A.T., J.M., J.G., K.A.L., R.P., L.C., D.M.D., C.F.A., R.E.O., M.K.A.); Pfizer Worldwide Research and Development, Groton, Connecticut (F.S., C.W.); Cantor Colburn LLP, Hartford, Connecticut (D.Z.); Kyowa Hakko Kirin Pharma, Princeton, New Jersey (F.B.); FORUM Pharmaceuticals, Waltham, Massachusetts (M.F.); GSK Consumer Healthcare, Parsippany, New Jersey (J.-S.W.); Bristol-Myers Squibb, Pennington, New Jersey (Jo.E.M., H.D.S., M.A.); Teva Pharmaceuticals, Frazer, Pennsylvania (M.G.); and Eisai, Woodcliff Lake, New Jersey (Q.H.)., Hoque N; Yale University, New Haven, Connecticut (J.H.T.); Bristol-Myers Squibb, Wallingford, Connecticut (K.M.B, J.R., Je.E.M., A.S.R., V.G., N.H., F.S., X.Z., W.C., K.S., R.R.D., L.A.T., J.M., J.G., K.A.L., R.P., L.C., D.M.D., C.F.A., R.E.O., M.K.A.); Pfizer Worldwide Research and Development, Groton, Connecticut (F.S., C.W.); Cantor Colburn LLP, Hartford, Connecticut (D.Z.); Kyowa Hakko Kirin Pharma, Princeton, New Jersey (F.B.); FORUM Pharmaceuticals, Waltham, Massachusetts (M.F.); GSK Consumer Healthcare, Parsippany, New Jersey (J.-S.W.); Bristol-Myers Squibb, Pennington, New Jersey (Jo.E.M., H.D.S., M.A.); Teva Pharmaceuticals, Frazer, Pennsylvania (M.G.); and Eisai, Woodcliff Lake, New Jersey (Q.H.)., Sweeney F; Yale University, New Haven, Connecticut (J.H.T.); Bristol-Myers Squibb, Wallingford, Connecticut (K.M.B, J.R., Je.E.M., A.S.R., V.G., N.H., F.S., X.Z., W.C., K.S., R.R.D., L.A.T., J.M., J.G., K.A.L., R.P., L.C., D.M.D., C.F.A., R.E.O., M.K.A.); Pfizer Worldwide Research and Development, Groton, Connecticut (F.S., C.W.); Cantor Colburn LLP, Hartford, Connecticut (D.Z.); Kyowa Hakko Kirin Pharma, Princeton, New Jersey (F.B.); FORUM Pharmaceuticals, Waltham, Massachusetts (M.F.); GSK Consumer Healthcare, Parsippany, New Jersey (J.-S.W.); Bristol-Myers Squibb, Pennington, New Jersey (Jo.E.M., H.D.S., M.A.); Teva Pharmaceuticals, Frazer, Pennsylvania (M.G.); and Eisai, Woodcliff Lake, New Jersey (Q.H.)., Zhuo X; Yale University, New Haven, Connecticut (J.H.T.); Bristol-Myers Squibb, Wallingford, Connecticut (K.M.B, J.R., Je.E.M., A.S.R., V.G., N.H., F.S., X.Z., W.C., K.S., R.R.D., L.A.T., J.M., J.G., K.A.L., R.P., L.C., D.M.D., C.F.A., R.E.O., M.K.A.); Pfizer Worldwide Research and Development, Groton, Connecticut (F.S., C.W.); Cantor Colburn LLP, Hartford, Connecticut (D.Z.); Kyowa Hakko Kirin Pharma, Princeton, New Jersey (F.B.); FORUM Pharmaceuticals, Waltham, Massachusetts (M.F.); GSK Consumer Healthcare, Parsippany, New Jersey (J.-S.W.); Bristol-Myers Squibb, Pennington, New Jersey (Jo.E.M., H.D.S., M.A.); Teva Pharmaceuticals, Frazer, Pennsylvania (M.G.); and Eisai, Woodcliff Lake, New Jersey (Q.H.)., Clarke W; Yale University, New Haven, Connecticut (J.H.T.); Bristol-Myers Squibb, Wallingford, Connecticut (K.M.B, J.R., Je.E.M., A.S.R., V.G., N.H., F.S., X.Z., W.C., K.S., R.R.D., L.A.T., J.M., J.G., K.A.L., R.P., L.C., D.M.D., C.F.A., R.E.O., M.K.A.); Pfizer Worldwide Research and Development, Groton, Connecticut (F.S., C.W.); Cantor Colburn LLP, Hartford, Connecticut (D.Z.); Kyowa Hakko Kirin Pharma, Princeton, New Jersey (F.B.); FORUM Pharmaceuticals, Waltham, Massachusetts (M.F.); GSK Consumer Healthcare, Parsippany, New Jersey (J.-S.W.); Bristol-Myers Squibb, Pennington, New Jersey (Jo.E.M., H.D.S., M.A.); Teva Pharmaceuticals, Frazer, Pennsylvania (M.G.); and Eisai, Woodcliff Lake, New Jersey (Q.H.)., Snow K; Yale University, New Haven, Connecticut (J.H.T.); Bristol-Myers Squibb, Wallingford, Connecticut (K.M.B, J.R., Je.E.M., A.S.R., V.G., N.H., F.S., X.Z., W.C., K.S., R.R.D., L.A.T., J.M., J.G., K.A.L., R.P., L.C., D.M.D., C.F.A., R.E.O., M.K.A.); Pfizer Worldwide Research and Development, Groton, Connecticut (F.S., C.W.); Cantor Colburn LLP, Hartford, Connecticut (D.Z.); Kyowa Hakko Kirin Pharma, Princeton, New Jersey (F.B.); FORUM Pharmaceuticals, Waltham, Massachusetts (M.F.); GSK Consumer Healthcare, Parsippany, New Jersey (J.-S.W.); Bristol-Myers Squibb, Pennington, New Jersey (Jo.E.M., H.D.S., M.A.); Teva Pharmaceuticals, Frazer, Pennsylvania (M.G.); and Eisai, Woodcliff Lake, New Jersey (Q.H.)., Denton RR; Yale University, New Haven, Connecticut (J.H.T.); Bristol-Myers Squibb, Wallingford, Connecticut (K.M.B, J.R., Je.E.M., A.S.R., V.G., N.H., F.S., X.Z., W.C., K.S., R.R.D., L.A.T., J.M., J.G., K.A.L., R.P., L.C., D.M.D., C.F.A., R.E.O., M.K.A.); Pfizer Worldwide Research and Development, Groton, Connecticut (F.S., C.W.); Cantor Colburn LLP, Hartford, Connecticut (D.Z.); Kyowa Hakko Kirin Pharma, Princeton, New Jersey (F.B.); FORUM Pharmaceuticals, Waltham, Massachusetts (M.F.); GSK Consumer Healthcare, Parsippany, New Jersey (J.-S.W.); Bristol-Myers Squibb, Pennington, New Jersey (Jo.E.M., H.D.S., M.A.); Teva Pharmaceuticals, Frazer, Pennsylvania (M.G.); and Eisai, Woodcliff Lake, New Jersey (Q.H.)., Zuev D; Yale University, New Haven, Connecticut (J.H.T.); Bristol-Myers Squibb, Wallingford, Connecticut (K.M.B, J.R., Je.E.M., A.S.R., V.G., N.H., F.S., X.Z., W.C., K.S., R.R.D., L.A.T., J.M., J.G., K.A.L., R.P., L.C., D.M.D., C.F.A., R.E.O., M.K.A.); Pfizer Worldwide Research and Development, Groton, Connecticut (F.S., C.W.); Cantor Colburn LLP, Hartford, Connecticut (D.Z.); Kyowa Hakko Kirin Pharma, Princeton, New Jersey (F.B.); FORUM Pharmaceuticals, Waltham, Massachusetts (M.F.); GSK Consumer Healthcare, Parsippany, New Jersey (J.-S.W.); Bristol-Myers Squibb, Pennington, New Jersey (Jo.E.M., H.D.S., M.A.); Teva Pharmaceuticals, Frazer, Pennsylvania (M.G.); and Eisai, Woodcliff Lake, New Jersey (Q.H.)., Thompson LA; Yale University, New Haven, Connecticut (J.H.T.); Bristol-Myers Squibb, Wallingford, Connecticut (K.M.B, J.R., Je.E.M., A.S.R., V.G., N.H., F.S., X.Z., W.C., K.S., R.R.D., L.A.T., J.M., J.G., K.A.L., R.P., L.C., D.M.D., C.F.A., R.E.O., M.K.A.); Pfizer Worldwide Research and Development, Groton, Connecticut (F.S., C.W.); Cantor Colburn LLP, Hartford, Connecticut (D.Z.); Kyowa Hakko Kirin Pharma, Princeton, New Jersey (F.B.); FORUM Pharmaceuticals, Waltham, Massachusetts (M.F.); GSK Consumer Healthcare, Parsippany, New Jersey (J.-S.W.); Bristol-Myers Squibb, Pennington, New Jersey (Jo.E.M., H.D.S., M.A.); Teva Pharmaceuticals, Frazer, Pennsylvania (M.G.); and Eisai, Woodcliff Lake, New Jersey (Q.H.)., Morrison J; Yale University, New Haven, Connecticut (J.H.T.); Bristol-Myers Squibb, Wallingford, Connecticut (K.M.B, J.R., Je.E.M., A.S.R., V.G., N.H., F.S., X.Z., W.C., K.S., R.R.D., L.A.T., J.M., J.G., K.A.L., R.P., L.C., D.M.D., C.F.A., R.E.O., M.K.A.); Pfizer Worldwide Research and Development, Groton, Connecticut (F.S., C.W.); Cantor Colburn LLP, Hartford, Connecticut (D.Z.); Kyowa Hakko Kirin Pharma, Princeton, New Jersey (F.B.); FORUM Pharmaceuticals, Waltham, Massachusetts (M.F.); GSK Consumer Healthcare, Parsippany, New Jersey (J.-S.W.); Bristol-Myers Squibb, Pennington, New Jersey (Jo.E.M., H.D.S., M.A.); Teva Pharmaceuticals, Frazer, Pennsylvania (M.G.); and Eisai, Woodcliff Lake, New Jersey (Q.H.)., Grace J; Yale University, New Haven, Connecticut (J.H.T.); Bristol-Myers Squibb, Wallingford, Connecticut (K.M.B, J.R., Je.E.M., A.S.R., V.G., N.H., F.S., X.Z., W.C., K.S., R.R.D., L.A.T., J.M., J.G., K.A.L., R.P., L.C., D.M.D., C.F.A., R.E.O., M.K.A.); Pfizer Worldwide Research and Development, Groton, Connecticut (F.S., C.W.); Cantor Colburn LLP, Hartford, Connecticut (D.Z.); Kyowa Hakko Kirin Pharma, Princeton, New Jersey (F.B.); FORUM Pharmaceuticals, Waltham, Massachusetts (M.F.); GSK Consumer Healthcare, Parsippany, New Jersey (J.-S.W.); Bristol-Myers Squibb, Pennington, New Jersey (Jo.E.M., H.D.S., M.A.); Teva Pharmaceuticals, Frazer, Pennsylvania (M.G.); and Eisai, Woodcliff Lake, New Jersey (Q.H.)., Berisha F; Yale University, New Haven, Connecticut (J.H.T.); Bristol-Myers Squibb, Wallingford, Connecticut (K.M.B, J.R., Je.E.M., A.S.R., V.G., N.H., F.S., X.Z., W.C., K.S., R.R.D., L.A.T., J.M., J.G., K.A.L., R.P., L.C., D.M.D., C.F.A., R.E.O., M.K.A.); Pfizer Worldwide Research and Development, Groton, Connecticut (F.S., C.W.); Cantor Colburn LLP, Hartford, Connecticut (D.Z.); Kyowa Hakko Kirin Pharma, Princeton, New Jersey (F.B.); FORUM Pharmaceuticals, Waltham, Massachusetts (M.F.); GSK Consumer Healthcare, Parsippany, New Jersey (J.-S.W.); Bristol-Myers Squibb, Pennington, New Jersey (Jo.E.M., H.D.S., M.A.); Teva Pharmaceuticals, Frazer, Pennsylvania (M.G.); and Eisai, Woodcliff Lake, New Jersey (Q.H.)., Furlong M; Yale University, New Haven, Connecticut (J.H.T.); Bristol-Myers Squibb, Wallingford, Connecticut (K.M.B, J.R., Je.E.M., A.S.R., V.G., N.H., F.S., X.Z., W.C., K.S., R.R.D., L.A.T., J.M., J.G., K.A.L., R.P., L.C., D.M.D., C.F.A., R.E.O., M.K.A.); Pfizer Worldwide Research and Development, Groton, Connecticut (F.S., C.W.); Cantor Colburn LLP, Hartford, Connecticut (D.Z.); Kyowa Hakko Kirin Pharma, Princeton, New Jersey (F.B.); FORUM Pharmaceuticals, Waltham, Massachusetts (M.F.); GSK Consumer Healthcare, Parsippany, New Jersey (J.-S.W.); Bristol-Myers Squibb, Pennington, New Jersey (Jo.E.M., H.D.S., M.A.); Teva Pharmaceuticals, Frazer, Pennsylvania (M.G.); and Eisai, Woodcliff Lake, New Jersey (Q.H.)., Wang JS; Yale University, New Haven, Connecticut (J.H.T.); Bristol-Myers Squibb, Wallingford, Connecticut (K.M.B, J.R., Je.E.M., A.S.R., V.G., N.H., F.S., X.Z., W.C., K.S., R.R.D., L.A.T., J.M., J.G., K.A.L., R.P., L.C., D.M.D., C.F.A., R.E.O., M.K.A.); Pfizer Worldwide Research and Development, Groton, Connecticut (F.S., C.W.); Cantor Colburn LLP, Hartford, Connecticut (D.Z.); Kyowa Hakko Kirin Pharma, Princeton, New Jersey (F.B.); FORUM Pharmaceuticals, Waltham, Massachusetts (M.F.); GSK Consumer Healthcare, Parsippany, New Jersey (J.-S.W.); Bristol-Myers Squibb, Pennington, New Jersey (Jo.E.M., H.D.S., M.A.); Teva Pharmaceuticals, Frazer, Pennsylvania (M.G.); and Eisai, Woodcliff Lake, New Jersey (Q.H.)., Lentz KA; Yale University, New Haven, Connecticut (J.H.T.); Bristol-Myers Squibb, Wallingford, Connecticut (K.M.B, J.R., Je.E.M., A.S.R., V.G., N.H., F.S., X.Z., W.C., K.S., R.R.D., L.A.T., J.M., J.G., K.A.L., R.P., L.C., D.M.D., C.F.A., R.E.O., M.K.A.); Pfizer Worldwide Research and Development, Groton, Connecticut (F.S., C.W.); Cantor Colburn LLP, Hartford, Connecticut (D.Z.); Kyowa Hakko Kirin Pharma, Princeton, New Jersey (F.B.); FORUM Pharmaceuticals, Waltham, Massachusetts (M.F.); GSK Consumer Healthcare, Parsippany, New Jersey (J.-S.W.); Bristol-Myers Squibb, Pennington, New Jersey (Jo.E.M., H.D.S., M.A.); Teva Pharmaceuticals, Frazer, Pennsylvania (M.G.); and Eisai, Woodcliff Lake, New Jersey (Q.H.)., Padmanabha R; Yale University, New Haven, Connecticut (J.H.T.); Bristol-Myers Squibb, Wallingford, Connecticut (K.M.B, J.R., Je.E.M., A.S.R., V.G., N.H., F.S., X.Z., W.C., K.S., R.R.D., L.A.T., J.M., J.G., K.A.L., R.P., L.C., D.M.D., C.F.A., R.E.O., M.K.A.); Pfizer Worldwide Research and Development, Groton, Connecticut (F.S., C.W.); Cantor Colburn LLP, Hartford, Connecticut (D.Z.); Kyowa Hakko Kirin Pharma, Princeton, New Jersey (F.B.); FORUM Pharmaceuticals, Waltham, Massachusetts (M.F.); GSK Consumer Healthcare, Parsippany, New Jersey (J.-S.W.); Bristol-Myers Squibb, Pennington, New Jersey (Jo.E.M., H.D.S., M.A.); Teva Pharmaceuticals, Frazer, Pennsylvania (M.G.); and Eisai, Woodcliff Lake, New Jersey (Q.H.)., Cook L; Yale University, New Haven, Connecticut (J.H.T.); Bristol-Myers Squibb, Wallingford, Connecticut (K.M.B, J.R., Je.E.M., A.S.R., V.G., N.H., F.S., X.Z., W.C., K.S., R.R.D., L.A.T., J.M., J.G., K.A.L., R.P., L.C., D.M.D., C.F.A., R.E.O., M.K.A.); Pfizer Worldwide Research and Development, Groton, Connecticut (F.S., C.W.); Cantor Colburn LLP, Hartford, Connecticut (D.Z.); Kyowa Hakko Kirin Pharma, Princeton, New Jersey (F.B.); FORUM Pharmaceuticals, Waltham, Massachusetts (M.F.); GSK Consumer Healthcare, Parsippany, New Jersey (J.-S.W.); Bristol-Myers Squibb, Pennington, New Jersey (Jo.E.M., H.D.S., M.A.); Teva Pharmaceuticals, Frazer, Pennsylvania (M.G.); and Eisai, Woodcliff Lake, New Jersey (Q.H.)., Wei C; Yale University, New Haven, Connecticut (J.H.T.); Bristol-Myers Squibb, Wallingford, Connecticut (K.M.B, J.R., Je.E.M., A.S.R., V.G., N.H., F.S., X.Z., W.C., K.S., R.R.D., L.A.T., J.M., J.G., K.A.L., R.P., L.C., D.M.D., C.F.A., R.E.O., M.K.A.); Pfizer Worldwide Research and Development, Groton, Connecticut (F.S., C.W.); Cantor Colburn LLP, Hartford, Connecticut (D.Z.); Kyowa Hakko Kirin Pharma, Princeton, New Jersey (F.B.); FORUM Pharmaceuticals, Waltham, Massachusetts (M.F.); GSK Consumer Healthcare, Parsippany, New Jersey (J.-S.W.); Bristol-Myers Squibb, Pennington, New Jersey (Jo.E.M., H.D.S., M.A.); Teva Pharmaceuticals, Frazer, Pennsylvania (M.G.); and Eisai, Woodcliff Lake, New Jersey (Q.H.)., Drexler DM; Yale University, New Haven, Connecticut (J.H.T.); Bristol-Myers Squibb, Wallingford, Connecticut (K.M.B, J.R., Je.E.M., A.S.R., V.G., N.H., F.S., X.Z., W.C., K.S., R.R.D., L.A.T., J.M., J.G., K.A.L., R.P., L.C., D.M.D., C.F.A., R.E.O., M.K.A.); Pfizer Worldwide Research and Development, Groton, Connecticut (F.S., C.W.); Cantor Colburn LLP, Hartford, Connecticut (D.Z.); Kyowa Hakko Kirin Pharma, Princeton, New Jersey (F.B.); FORUM Pharmaceuticals, Waltham, Massachusetts (M.F.); GSK Consumer Healthcare, Parsippany, New Jersey (J.-S.W.); Bristol-Myers Squibb, Pennington, New Jersey (Jo.E.M., H.D.S., M.A.); Teva Pharmaceuticals, Frazer, Pennsylvania (M.G.); and Eisai, Woodcliff Lake, New Jersey (Q.H.)., Macor JE; Yale University, New Haven, Connecticut (J.H.T.); Bristol-Myers Squibb, Wallingford, Connecticut (K.M.B, J.R., Je.E.M., A.S.R., V.G., N.H., F.S., X.Z., W.C., K.S., R.R.D., L.A.T., J.M., J.G., K.A.L., R.P., L.C., D.M.D., C.F.A., R.E.O., M.K.A.); Pfizer Worldwide Research and Development, Groton, Connecticut (F.S., C.W.); Cantor Colburn LLP, Hartford, Connecticut (D.Z.); Kyowa Hakko Kirin Pharma, Princeton, New Jersey (F.B.); FORUM Pharmaceuticals, Waltham, Massachusetts (M.F.); GSK Consumer Healthcare, Parsippany, New Jersey (J.-S.W.); Bristol-Myers Squibb, Pennington, New Jersey (Jo.E.M., H.D.S., M.A.); Teva Pharmaceuticals, Frazer, Pennsylvania (M.G.); and Eisai, Woodcliff Lake, New Jersey (Q.H.)., Albright CF; Yale University, New Haven, Connecticut (J.H.T.); Bristol-Myers Squibb, Wallingford, Connecticut (K.M.B, J.R., Je.E.M., A.S.R., V.G., N.H., F.S., X.Z., W.C., K.S., R.R.D., L.A.T., J.M., J.G., K.A.L., R.P., L.C., D.M.D., C.F.A., R.E.O., M.K.A.); Pfizer Worldwide Research and Development, Groton, Connecticut (F.S., C.W.); Cantor Colburn LLP, Hartford, Connecticut (D.Z.); Kyowa Hakko Kirin Pharma, Princeton, New Jersey (F.B.); FORUM Pharmaceuticals, Waltham, Massachusetts (M.F.); GSK Consumer Healthcare, Parsippany, New Jersey (J.-S.W.); Bristol-Myers Squibb, Pennington, New Jersey (Jo.E.M., H.D.S., M.A.); Teva Pharmaceuticals, Frazer, Pennsylvania (M.G.); and Eisai, Woodcliff Lake, New Jersey (Q.H.)., Gasior M; Yale University, New Haven, Connecticut (J.H.T.); Bristol-Myers Squibb, Wallingford, Connecticut (K.M.B, J.R., Je.E.M., A.S.R., V.G., N.H., F.S., X.Z., W.C., K.S., R.R.D., L.A.T., J.M., J.G., K.A.L., R.P., L.C., D.M.D., C.F.A., R.E.O., M.K.A.); Pfizer Worldwide Research and Development, Groton, Connecticut (F.S., C.W.); Cantor Colburn LLP, Hartford, Connecticut (D.Z.); Kyowa Hakko Kirin Pharma, Princeton, New Jersey (F.B.); FORUM Pharmaceuticals, Waltham, Massachusetts (M.F.); GSK Consumer Healthcare, Parsippany, New Jersey (J.-S.W.); Bristol-Myers Squibb, Pennington, New Jersey (Jo.E.M., H.D.S., M.A.); Teva Pharmaceuticals, Frazer, Pennsylvania (M.G.); and Eisai, Woodcliff Lake, New Jersey (Q.H.)., Olson RE; Yale University, New Haven, Connecticut (J.H.T.); Bristol-Myers Squibb, Wallingford, Connecticut (K.M.B, J.R., Je.E.M., A.S.R., V.G., N.H., F.S., X.Z., W.C., K.S., R.R.D., L.A.T., J.M., J.G., K.A.L., R.P., L.C., D.M.D., C.F.A., R.E.O., M.K.A.); Pfizer Worldwide Research and Development, Groton, Connecticut (F.S., C.W.); Cantor Colburn LLP, Hartford, Connecticut (D.Z.); Kyowa Hakko Kirin Pharma, Princeton, New Jersey (F.B.); FORUM Pharmaceuticals, Waltham, Massachusetts (M.F.); GSK Consumer Healthcare, Parsippany, New Jersey (J.-S.W.); Bristol-Myers Squibb, Pennington, New Jersey (Jo.E.M., H.D.S., M.A.); Teva Pharmaceuticals, Frazer, Pennsylvania (M.G.); and Eisai, Woodcliff Lake, New Jersey (Q.H.)., Hong Q; Yale University, New Haven, Connecticut (J.H.T.); Bristol-Myers Squibb, Wallingford, Connecticut (K.M.B, J.R., Je.E.M., A.S.R., V.G., N.H., F.S., X.Z., W.C., K.S., R.R.D., L.A.T., J.M., J.G., K.A.L., R.P., L.C., D.M.D., C.F.A., R.E.O., M.K.A.); Pfizer Worldwide Research and Development, Groton, Connecticut (F.S., C.W.); Cantor Colburn LLP, Hartford, Connecticut (D.Z.); Kyowa Hakko Kirin Pharma, Princeton, New Jersey (F.B.); FORUM Pharmaceuticals, Waltham, Massachusetts (M.F.); GSK Consumer Healthcare, Parsippany, New Jersey (J.-S.W.); Bristol-Myers Squibb, Pennington, New Jersey (Jo.E.M., H.D.S., M.A.); Teva Pharmaceuticals, Frazer, Pennsylvania (M.G.); and Eisai, Woodcliff Lake, New Jersey (Q.H.)., Soares HD; Yale University, New Haven, Connecticut (J.H.T.); Bristol-Myers Squibb, Wallingford, Connecticut (K.M.B, J.R., Je.E.M., A.S.R., V.G., N.H., F.S., X.Z., W.C., K.S., R.R.D., L.A.T., J.M., J.G., K.A.L., R.P., L.C., D.M.D., C.F.A., R.E.O., M.K.A.); Pfizer Worldwide Research and Development, Groton, Connecticut (F.S., C.W.); Cantor Colburn LLP, Hartford, Connecticut (D.Z.); Kyowa Hakko Kirin Pharma, Princeton, New Jersey (F.B.); FORUM Pharmaceuticals, Waltham, Massachusetts (M.F.); GSK Consumer Healthcare, Parsippany, New Jersey (J.-S.W.); Bristol-Myers Squibb, Pennington, New Jersey (Jo.E.M., H.D.S., M.A.); Teva Pharmaceuticals, Frazer, Pennsylvania (M.G.); and Eisai, Woodcliff Lake, New Jersey (Q.H.)., AbuTarif M; Yale University, New Haven, Connecticut (J.H.T.); Bristol-Myers Squibb, Wallingford, Connecticut (K.M.B, J.R., Je.E.M., A.S.R., V.G., N.H., F.S., X.Z., W.C., K.S., R.R.D., L.A.T., J.M., J.G., K.A.L., R.P., L.C., D.M.D., C.F.A., R.E.O., M.K.A.); Pfizer Worldwide Research and Development, Groton, Connecticut (F.S., C.W.); Cantor Colburn LLP, Hartford, Connecticut (D.Z.); Kyowa Hakko Kirin Pharma, Princeton, New Jersey (F.B.); FORUM Pharmaceuticals, Waltham, Massachusetts (M.F.); GSK Consumer Healthcare, Parsippany, New Jersey (J.-S.W.); Bristol-Myers Squibb, Pennington, New Jersey (Jo.E.M., H.D.S., M.A.); Teva Pharmaceuticals, Frazer, Pennsylvania (M.G.); and Eisai, Woodcliff Lake, New Jersey (Q.H.)., Ahlijanian MK; Yale University, New Haven, Connecticut (J.H.T.); Bristol-Myers Squibb, Wallingford, Connecticut (K.M.B, J.R., Je.E.M., A.S.R., V.G., N.H., F.S., X.Z., W.C., K.S., R.R.D., L.A.T., J.M., J.G., K.A.L., R.P., L.C., D.M.D., C.F.A., R.E.O., M.K.A.); Pfizer Worldwide Research and Development, Groton, Connecticut (F.S., C.W.); Cantor Colburn LLP, Hartford, Connecticut (D.Z.); Kyowa Hakko Kirin Pharma, Princeton, New Jersey (F.B.); FORUM Pharmaceuticals, Waltham, Massachusetts (M.F.); GSK Consumer Healthcare, Parsippany, New Jersey (J.-S.W.); Bristol-Myers Squibb, Pennington, New Jersey (Jo.E.M., H.D.S., M.A.); Teva Pharmaceuticals, Frazer, Pennsylvania (M.G.); and Eisai, Woodcliff Lake, New Jersey (Q.H.) Michael.ahlijanian@bms.com.

Publikováno v: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2016 Jul; Vol. 358 (1), pp. 125-37. Date of Electronic Publication: 2016 Apr 20.

Zobrazit plný text záznamu

Akademický článek

Identification and Preclinical Pharmacology of the γ-Secretase Modulator BMS-869780.

Autor: Toyn JH; Exploratory Biology and Genomics, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Thompson LA; Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Lentz KA; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Meredith JE Jr; Exploratory Biology and Genomics, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Burton CR; Exploratory Biology and Genomics, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Sankaranararyanan S; Exploratory Biology and Genomics, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Guss V; Exploratory Biology and Genomics, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Hall T; Exploratory Biology and Genomics, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA ; Preclinical Sciences, Alexion Pharmaceuticals, Inc 352 Knotter Drive, Cheshire, CT 06410, USA., Iben LG; Exploratory Biology and Genomics, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Krause CM; Exploratory Biology and Genomics, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Krause R; Exploratory Biology and Genomics, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Lin XA; Exploratory Biology and Genomics, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Pierdomenico M; Exploratory Biology and Genomics, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Polson C; Exploratory Biology and Genomics, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Robertson AS; Exploratory Biology and Genomics, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Denton RR; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Grace JE; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Morrison J; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Raybon J; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Zhuo X; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Snow K; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Padmanabha R; Lead Discovery and Lead Profiling, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Agler M; Lead Discovery and Lead Profiling, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA ; High Throughput Biology, Boehringer Ingelheim, 900 Ridgebury Road, Ridgefield, CT 06877, USA., Esposito K; Lead Discovery and Lead Profiling, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Harden D; Lead Discovery and Lead Profiling, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Prack M; Lead Discovery and Lead Profiling, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Varma S; Lead Discovery and Lead Profiling, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA ; Stratford High School, 45 North Parade, Stratford, CT 06615, USA., Wong V; Lead Discovery and Lead Profiling, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA ; External Research Solutions, WWMC, Pfizer World Wide Research & Development, Eastern Point Road, Groton, CT 06340, USA., Zhu Y; Lead Discovery and Lead Profiling, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA ; Arvinas Inc, 5 Science Park, New Haven, CT 06511, USA., Zvyaga T; Lead Discovery and Lead Profiling, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Gerritz S; Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Marcin LR; Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Higgins MA; Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Shi J; Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Wei C; Discovery Analytical Sciences, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA ; Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer World Wide Research & Development, Eastern Point Road, Groton, CT 06340, USA., Cantone JL; Discovery Analytical Sciences, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Drexler DM; Discovery Analytical Sciences, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Macor JE; Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Olson RE; Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Ahlijanian MK; Exploratory Biology and Genomics, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA., Albright CF; Exploratory Biology and Genomics, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA.

Publikováno v: International journal of Alzheimer's disease [Int J Alzheimers Dis] 2014; Vol. 2014, pp. 431858. Date of Electronic Publication: 2014 Jul 08.

Zobrazit plný text záznamu

Akademický článek

Pharmacodynamics of selective inhibition of γ-secretase by avagacestat.

Autor: Albright CF; Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut 06492, USA. charlie.albright@bms.com, Dockens RC, Meredith JE Jr, Olson RE, Slemmon R, Lentz KA, Wang JS, Denton RR, Pilcher G, Rhyne PW, Raybon JJ, Barten DM, Burton C, Toyn JH, Sankaranarayanan S, Polson C, Guss V, White R, Simutis F, Sanderson T, Gillman KW, Starrett JE Jr, Bronson J, Sverdlov O, Huang SP, Castaneda L, Feldman H, Coric V, Zaczek R, Macor JE, Houston J, Berman RM, Tong G

Publikováno v: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2013 Mar; Vol. 344 (3), pp. 686-95. Date of Electronic Publication: 2012 Dec 28.

Zobrazit plný text záznamu

Akademický článek

Differential autoregulation of glucocorticoid receptor expression in human T- and B-cell lines.

Autor: Denton RR; Department of Pharmacology, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814-4799., Eisen LP, Elsasser MS, Harmon JM

Publikováno v: Endocrinology [Endocrinology] 1993 Jul; Vol. 133 (1), pp. 248-56.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání